NCT03501550View on ClinicalTrials.gov

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

January 8, 2019

Study Completion Date

June 7, 2019

Conditions
Chronic Hepatitis C
Interventions
DRUG

CDI-31244

investigational drug

DRUG

SOF/VEL

sofosbuvir and velpatasvir fixed dose combination

Trial Locations (1)

21201

Institute of Human Virology University of Maryland, Baltimore

Sponsors
All Listed Sponsors
lead

Cocrystal Pharma, Inc.

INDUSTRY